Bapotulimab

巴泊妥利单抗

Report date: 2024/06/27 10:12:51

Base Information

Drug NameBapotulimab
Drug Alias NameCGEN-15001T programCGEN-15001T-targeted mAbCGEN-15001T-targeted monoclonal antibodyBAY-1905254
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionImmunoglobulin-like domain-containing receptor 2 antagonists
TargetsImmunoglobulin-like domain-containing receptor 2
Therapy Area/IndicationsSolid tumoursSquamous Cell Carcinoma of Head and Neck
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesCompugen Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBayer AG
Inactive CompaniesN/A
Active IndicationsSolid tumoursSquamous Cell Carcinoma of Head and Neck
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A